Aurora Spine Corporation , a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, announced today that it has received U.S. FDA 510(k) clearance for its proprietary APOLLO Anterior Cervical Plate (ACP) system, featuring a sleek 1.9mm design, with Hyper-Angulation™ variability in the Cephalad-Caudal screw angulation of 32° – Freedom to Angulate™.

The new ACP system challenges the status quo of cervical spine technology. It is designed to help reduce common postoperative complications, such as dysphagia, malalignment, and adjacent level ossification, by enabling surgeons to customize treatment to patient needs versus a traditional one-size-fits-all approach, and consists of:

• Freedom to Angulate, including Hyper-Angulation™ screw variability, to optimized performance for each surgical level to support construct stability.
• A wide array of implant length options to match a variety of patient anatomies and to facilitate maximizing the distance from the adjacent levels; and
• A range of advanced screw offerings with fixed and variable angles to enable better screw placement and locking accuracy.
• APOLLO™ is part the DEXA™ family of products: positioned to reshape the market through patent focused innovation and address the next advancement in spine surgery – DEXA Interbody Technology.

“There are an estimated 180,000 cervical fusion procedures performed in the United States each year to relieve compression on the spinal cord or nerve roots. Receiving FDA 510(k) clearance for the APOLLO™ (ACP) system reflects Aurora Spine’s commitment to deliver innovative, modern technology for the anterior cervical spine and to support positive clinical outcomes,” said Trent Northcutt, President and CEO, at Aurora Spine. “The launch of APOLLO™ (ACP) is key to our long-term cervical implant strategy and represents a significant opportunity for growth, as cervical spine procedures comprise an approximately $2.6 billion segment of the global spine market.”

Mr. Northcutt added, “This approval is an important piece to the puzzle for advancing Aurora Spine’s key initiative of bringing more proprietary-based products to the marketplace and decreasing our reliance on third-party products. Sales of cervical plates in fiscal 2019 represented approximately 10% of revenues for Aurora and the APOLLO plate will enable Aurora to convert another portion of the company’s revenue base into a proprietary product and allow us to capture higher margins. This new product will also support sales of our TiNANO™ cervical cages and enable us to develop additional products around our DEXA™ patent, which matches implants to a patient’s bone density. This approval is a great step for Aurora in fiscal 2021 and we are hopeful to deliver several new key products throughout the year.”

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant and pain management markets through a series of innovative, minimally invasive, regenerative spinal implant technologies.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Leading NMR diagnostics company numares AG announced that the company made a 510(k) submission to the U.S. FDA for its AXINON® IVD System, a NMR-platform for AI-driven, metabolomics-based diagnostics. If cleared, AXINON® would become the first NMR-based clinical laboratory system using AI-evaluated metabolic data. Several multi-marker assays for AXINON® will cover numerous unmet medical needs, in order to prevent, diagnose and treat disease.

The clearance of AXINON® would bring a novel diagnostic approach to clinical laboratories, the combination of several metabolic biomarkers, so-called metabolite constellations, analyzed by advanced nuclear magnetic resonance (NMR) technology and evaluated by numares’ proprietary, AI-driven AXINON® diagnostic software.

“This U.S. regulatory filing for its diagnostics platform is an important milestone for numares,” said Winton Gibbons, President – US and co-Chief Executive Officer of numares. “After entering into collaborations on joint diagnostics development with analytical instrumentation and solution provider Bruker Corporation in January 2021, and with Mayo Clinic Laboratories in 2019, this FDA submission is the first step in our common endeavor to bring NMR diagnostics into routine clinical use, and make metabolomics-based diagnostics accessible to the patients.”

numares is currently developing multi-marker algorithms for several diagnostic tests on the AXINON® IVD System. These include AXINON® GFRNMR to reliably assess kidney function by improved determination of glomerular filtration rate (GFR). numares expects to submit this test to the FDA also in the first half 2021. The third assay AXINON® renalTX-SCORE® is intended to reliably identify early kidney rejection in post-transplant surveillance, and be submitted to the FDA in 2022. Further multi-marker tests are in development, e.g., for liver disease, cancer detection, and multiple sclerosis.

Dr. Maulik Shah, numares’ Medical Director comments: “AXINON® provides clinical laboratories with a powerful technology that leverages the information-rich metabolome with artificial intelligence to give healthcare professionals new insights into disease diagnosis and management for improved patient outcomes. At the same time, automation capabilities, excellent precision, easy operability will allow easy adaption of the FDA-cleared system by clinical laboratories and will make AXINON® an indispensable routine diagnostic tool in precision medicine.”

“The 510(k) submission of our AXINON® System is an important step and prerequisite to further strengthen commercialization of numares’ products in the United States”, concludes Dr. Volker Pfahlert, co-CEO of numares and chairman of the executive board. “Metabolic disorders are a rapidly increasing problem and major challenge to today’s healthcare systems. Patients will benefit from our approach to consider the patient’s metabolome with sophisticated algorithms. Once cleared by the FDA, we believe AXINON® has the potential to meaningfully improve health outcomes and quality of life for millions of patients.”

The AXINON® System consists of AI-based AXINON® Software, ready-to-use AXINON® kits, and an advanced NMR technology, refined by numares’ proprietary Magnetic Group SignalingTM to ensure highly standardized and automated processing of serum or urine samples in high-throughput.

Azalea Health Innovations, Inc. (Azalea), a leading provider of cloud-based patient management and health IT solutions, announced an expansion to their COVID-19 Essentials Pack that includes new features to track vaccinations and seamlessly report them to state agencies. The interoperable platform can also be easily integrated with patient engagement solutions to support vaccination outreach. As new variants raise the stakes for vaccination, the EHR update enables real-time immunization reporting and more efficient vaccine distribution, while relieving the administrative burden on overwhelmed clinicians.

The new features in the COVID-19 Essentials Pack make it easy for community health providers to track their vaccine inventory and add patients’ vaccination status to their medical history. Azalea’s interoperable solution means vaccination reports can automatically be sent to state registries if providers choose to, enabling public health officials to allocate vaccines more effectively. The Essentials Pack previously updated the EHR with COVID-19 diagnosis codes to add to patients’ medical history, COVID-19 lab codes for billing, and a COVID-19 assessment questionnaire module for syndromic surveillance that can be plugged into Azalea’s customizable EHR workflows.

“Like many of us, healthcare providers have endured great hardship in the last year, and we’re proud to help them vaccinate their patients quickly and bring this pandemic to an end,” said Baha Zeidan, CEO and co-founder of Azalea. “The human and financial toll of the pandemic has been dire for many hospitals, particularly smaller hospitals in underserved communities. We cannot allow administrative hurdles to slow down the vaccination process and delay healthcare’s recovery from the pandemic.

With the update to the COVID-19 Essentials Pack, providers can filter their patient population for vulnerable groups, such as the elderly and those with chronic conditions, and automate vaccination outreach to these patients through the patient portal broadcast messaging feature. Providers can also send paperwork through the patient portal to minimize in-person contact and administrative work. Azalea’s EHR is fully interoperable with the SMART on FHIR API standard, so it’s easy to integrate third-party patient engagement apps to support outreach efforts as well.

Azalea has been committed to helping community healthcare providers weather the pandemic since the beginning. Within hours of the National Emergency Declaration, Azalea announced that it would provide a year of free telehealth services for EHR customers. Azalea’s platform has also helped hospitals like DeWitt Hospital connect to health information exchanges, track COVID-19 testing, recover lost revenue, and maintain continuity of care through the ongoing crisis.

About Azalea Health Innovations, Inc.:

Azalea is changing the way health IT platforms connect community-based healthcare providers and patients across the care continuum. Offering a 100% cloud-based, interoperable solution, Azalea delivers electronic health records, revenue cycle management, and a fully integrated telehealth solution designed for rural, community and urban practices and hospitals, especially those focused on underserved populations. Quick to deploy and intuitive to use, Azalea solutions ensure better care coordination and communication, and the “one patient, one record” approach provides care teams the agility to achieve better outcomes. The Azalea platform also delivers tools and resources to help providers meet their Meaningful Use requirements, and informs their strategies to navigate accountable care and alternative payment models.

Creative Medical Technology Holdings, Inc., a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced its intent to launch Virtual Physician™ focused on telehealth solutions for regenerative medicine this summer.

The company will initially utilize the platform to educate, recruit and retain patients for their already commercialized proprietary procedures in partnership with their national network of providers:

As additional products are commercialized, (i.e. StemSpine® – Regenerative Stem Cell Procedure for Treatment of Degenerative Disc Disease), the platform will expand to include these products.

Furthermore, the company plans to build out Virtual Physician™ to include additional products outside of their proprietary procedures focused on regenerative medicine. “While our primary interest is in supporting our providers and to educate, recruit and retain patients for our proprietary procedures through this innovative platform, we are also aware of the power of telehealth to accelerate acceptance for regenerative medicine more broadly”, said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc. “While several telehealth companies have emerged (i.e. Teladoc with market cap of $29B; HIMS & HERS Health with market cap of $2.5B), none address this area of breakthrough medicine. As a company at the forefront of this cutting-edge industry, we see it as our responsibility to drive broad adoption.

Virtual Physician creates three unique opportunities to drive shareholder value:

• Management Service Organization : Charging a fee per qualified patient to providers – conversations with existing providers validates this as highly valuable
• Royalty for promotion of products from external partners: As the platform grows in popularity, company can charge a fee from other manufacturers for featuring their products
• Direct sales of ancillary products to consumers on platform: Become a one-stop shop for our patients by curating and consolidating additional products to improve underlying medical conditions

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative medicine-stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics and is listed on the OTC under the ticker symbol CELZ.

Omnicell Inc, a leading provider of medication and supply management solutions and adherence tools for healthcare systems and pharmacies, will unveil its latest robotic dispensing system – Medimat – to the Middle East pharmaceutical industry at this year’s DUPHAT Conference and Exhibition (5-7 April 2021), DWTC, Dubai.

The next generation Medimat is the latest enhancement to Omnicell’s portfolio of technologies for central pharmacy workflows, helping to dramatically improve all aspects of the dispensing process. By simplifying the dispensing process and minimising the number of human interactions in the pharmacy workflow, Medimat will further reduce the potential for errors.

For pharmacists in particular, a lack of inventory precision and control can result in large quantities of expired stock and significant monetary losses for hospitals. Smarter and safer medication management technology is key to reducing the burden on healthcare teams, ensuring they can provide the right medication, at the right dose, at the right time.

“Automation has become an integral part of any healthcare setting and we are committed to the continual development of our technologies in order to support the vital process of medication and supply management,” said Sara Dalmasso, International Vice President and General Manager for Omnicell International. “We are thrilled to be a part of such a well-respected and dedicated platform as DUPHAT. The event will provide an outstanding opportunity to introduce Medimat to healthcare professionals in the region, as well as showcase Omnicell’s other industry-leading solutions.

Medimat will support the healthcare industry by improving efficiency, driving savings and freeing up staff from administrative and logistical tasks, such as unpacking medication, stock management and searching for medication. Crucially, it will enable pharmacists to spend more time on clinical work and building patient relationships.”

Additional benefits of Medimat include:

• Pharmacists will know where the drug is within the robot and what quantities are available.
• Ability to track slow-moving items and eliminate wasted or out-of-date stock.
• Ability to generate a real time report on stock usage, so manual stock counts are no longer needed, saving valuable time.
• Highly effective scan station means inputting of medication supports safety.
• Direct mode option enables users to have medication available for immediate dispensing.
• Speed of the robot will allow for more prescriptions to be processed with a higher level of accuracy – input speed of up to 750 packs per hour. *

Omnicell will also be showcasing its range of point of care solutions at this year’s event including Omnicell XT Automated Dispensing Cabinets for medication management, RFID Cabinet for hospital inventory as well as our new software solutions SupplyX which tracks all inventory moving through healthcare settings while providing real time data insights.

Omnicell technology has been supporting healthcare providers in the Middle East for 17 years, including King Faisal Specialist Hospital (KSA), National Guard Health Affairs (KSA) and Dubai Health Authority (UAE). The Company’s proven and streamlined range of solutions and services are designed to reduce medication dispensing errors, improve patient safety, drive efficiency and allow healthcare professionals to spend more time on face-to-face patient care.

About Omnicell
Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 50,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions.

About DUPHAT

Dubai International Pharmaceuticals & Technologies Conference and Exhibition (DUPHAT) takes place from 5-7 April 2021 at the DWTC, Dubai. Established in 1995, DUPHAT has quickly established itself as the unique pharma event for the Middle East and North Africa markets with some of the top 100 global pharma companies branding it as the ‘must-attend’ event for the pharmaceutical industry in the region. It endeavours to provide a complete solution to the pharma industry, from manufacture to supply to the end consumer.

A caregiver is needed for a variety of purposes – not only in families but also elsewhere such as at the scene of natural calamities. This is the reason we have different categories of caregivers who are well-versed in giving care under specific situations. For the purpose of assistance of people with health conditions, there are health caregivers who take care of the entire routine of the concerned person related to health such as eating, exercising, and much more.

Here’s What You Should Do To Find The Ideal Caregiver

Since a lot depends on the caregivers in such cases, you must know how to choose the right one for you. For an elderly person with a chronic disease, it is important to go with a medical caregiver who has experience because at every point you want to be sure that you are doing the right thing, taking the right medications, and following the correct routine. The professionals behind Freedomcare point out that a relative, or a friend can serve as a caregiver. So, how do you find a caregiver that is best for you? Well, let us figure it out with some useful tips:

Access Your Needs

The first thing that you need to do is to evaluate the help that you require. Is it health care, personal care, or household care? You need will define what kind of caregiver will be right for you. Make a list and put down everything you need assistance with. At the end of it, you will have a clear idea of all that you need.

Draft A Job Description

Well, you can go the traditional method too in which you would ask your family members and friends to find a caregiver. Not to mention, it is going to take a lot of time. However, if you want to get the ideal caregiver as soon as possible, you must ideally roll out a job description. Once you make a job description, you can expect to get applications immediately. What is implied, you will have many options to choose from.

Interview The Applicants

If you want you can do it yourself, or you can get somebody you trust to interview the applicants. Interviewing is the most important step that allows you to know the applicants in person. You can see who fits you and who does not. With a set of specific questions, you can figure if the applicant is capable of handling areas of your life that you need help with.

Check References

You know that a lot is going to depend on your caregiver, hence you want somebody who can be trusted and is dependable. Speaking with people who have given references will be very helpful in getting a better idea about your potential caregiver. You should not miss this step out.

Finding a caregiver is certainly not very difficult. But getting the high one may be a struggle for many. But there are ways you can make sure the one who is going to be with you is dependable, trustworthy, and hard-working. Follow the above-mentioned methods and you can expect to get a good caregiver.